lilly glp-1 drugs Orforglipron: Eli Lilly's New Oral Weight-loss Pill Lilly launches GLP-1 pill, kicking

Purpose Glucagon-like receptor agonists (GLP1-RAs) have raised peri-procedural concerns due to their potential to delay gastric emptying

A new blockbuster class of therapeutics, glucagon-like peptide 1 (GLP-1) analogs (eg, semaglutide), shows promise at curbing both diseases

The formula acts as a natural appetite suppressant, supports metabolism, balances hunger, and promotes energy

Ascletis ASC35, a once-monthly GLP-1/GIP peptide using a self-assembling lipid depot, cleared FDA IND for Phase 1 head-to-head vs weekly tirzepatide June 23.

Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.